

## Committee Print

[SHOWING THE TEXT OF H.R. 5353 AS FORWARDED BY THE SUBCOMMITTEE  
ON HEALTH ON APRIL 25, 2018]

115TH CONGRESS  
2D SESSION

# H. R. 5353

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

---

### IN THE HOUSE OF REPRESENTATIVES

MARCH 20, 2018

Mr. LANCE (for himself, Mr. KENNEDY, Mr. COLLINS of New York, Ms. ESHOO, Mr. BARTON, and Ms. MATSUI) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Eliminating Opioid Re-  
5 lated Infectious Diseases Act of 2018”.

1 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**  
2 **OF SURVEILLANCE AND EDUCATION RE-**  
3 **GARDING INFECTIONS ASSOCIATED WITH IL-**  
4 **LICIT DRUG USE AND OTHER RISK FACTORS.**

5 Section 317N of the Public Health Service Act (42  
6 U.S.C. 247b–15) is amended to read as follows:

7 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**  
8 **INFECTIONS ASSOCIATED WITH ILLICIT**  
9 **DRUG USE AND OTHER RISK FACTORS.**

10 “(a) IN GENERAL.—The Secretary may (directly and  
11 through grants to public and nonprofit private entities)  
12 provide for programs for the following:

13 “(1) To cooperate with the States in imple-  
14 menting or maintaining a surveillance system to de-  
15 termine the incidence of infections commonly associ-  
16 ated with illicit drug use, including infections com-  
17 monly associated with injection drug use such as  
18 viral hepatitis, human immunodeficiency virus, and  
19 infective endocarditis, and to assist the States in de-  
20 termining the prevalence of such infections, which  
21 may include the reporting of cases of such infec-  
22 tions.

23 “(2) To identify, counsel, and offer testing to  
24 individuals who are at risk of infections as a result  
25 of injection drug use, receiving blood transfusions  
26 prior to July 1992, or other risk factors.

1           “(3) To provide appropriate referrals for coun-  
2           seling, testing, and medical treatment of individuals  
3           identified under paragraph (2) and to ensure, to the  
4           extent practicable, the provision of appropriate fol-  
5           low-up services.

6           “(4) To develop and disseminate public infor-  
7           mation and education programs for the detection  
8           and control of infections described in paragraph (1),  
9           with priority given to high-risk populations as deter-  
10          mined by the Secretary.

11          “(5) To improve the education, training, and  
12          skills of health professionals in the detection and  
13          control of infections and the coordination of treat-  
14          ment of addiction and infectious diseases described  
15          in paragraph (1), with priority given to substance  
16          use disorder treatment providers, pediatricians and  
17          other primary care providers, obstetrician-gyne-  
18          cologists, infectious diseases clinicians, and HIV cli-  
19          nicians.

20          “(b) LABORATORY PROCEDURES.—The Secretary  
21          may (directly or through grants to public and nonprofit  
22          private entities) carry out programs to provide for im-  
23          provements in the quality of clinical-laboratory procedures  
24          regarding infections described in subsection (a)(1).

1           “(c) DEFINITIONS.—In this section, the term ‘injec-  
2    tion drug use’ means—

3           “(1) intravenous administration of a substance  
4           in schedule I under section 202 of the Controlled  
5           Substances Act;

6           “(2) intravenous administration of a substance  
7           in schedule II, III, IV, or V under section 202 of the  
8           Controlled Substances Act that has not been ap-  
9           proved for intravenous use under—

10           “(A) section 505 of the Federal Food,  
11           Drug and Cosmetic Act; or

12           “(B) section 351 of the Public Health  
13           Service Act; or

14           “(3) intravenous administration of a substance  
15           in schedule II, III, IV, or V under section 202 of the  
16           Controlled Substances Act that has not been pre-  
17           scribed to the person using the substance.

18           “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
19           purpose of carrying out this section, there are authorized  
20           to be appropriated \$40,000,000 for each of the fiscal years  
21           2019 through 2023.”.